Literature DB >> 29268415

Optimal managements of stage IIIA (N2) non-small cell lung cancer patients: a population-based survival analysis.

Zhaofei Pang1, Yufan Yang1, Nan Ding1, Cuicui Huang1, Tiehong Zhang2, Yang Ni2, Jiajun Du1,3, Qi Liu1.   

Abstract

BACKGROUND: This study aimed to investigate the optimal management of stage IIIA (cN2) non-small cell lung cancer (NSCLC) patients and determine potential predictive factors.
METHODS: We extracted patients diagnosed as NSCLC stage IIIA (cN2) between 2004 and 2011 from Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and lung cancer-specific survival (LCSS) were compared among patients given different clinical managements by Kaplan-Meier method. Other variables such as age, sex and tumor size were analyzed to explore the factors associated with outcomes.
RESULTS: A total of 98,700 IIIA-cN2 NSCLC patients were identified from SEER database. Survival of patients treated with surgery was better than that of patients treated by radiotherapy alone (P<0.001). Radiation prior to surgery significantly improved the survival in comparison with surgery alone (P<0.001). In the subgroups of OS analysis, age >65 (P=0.902), adenocarcinoma (P=0.279), tumor size ≤3 cm (P=0.170), well differentiated (P=0.360) patients, preoperative radiotherapy improved survival insignificantly compared with surgery alone.
CONCLUSIONS: Preoperative radiation with surgery had the most encouraging survival outcomes in stage IIIA-cN2 NSCLC patients compared with radiation or surgery alone. No significant outcome improvement was shown between postoperative radiotherapy (PORT) and surgery alone.

Entities:  

Keywords:  Stage IIIA (N2); non-small cell lung cancer (NSCLC); postoperative radiotherapy (PORT); preoperative radiotherapy; radiotherapy; surgery

Year:  2017        PMID: 29268415      PMCID: PMC5723778          DOI: 10.21037/jtd.2017.10.47

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  32 in total

1.  A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancer.

Authors:  Richard J Stephens; David J Girling; Penelope Hopwood; Nicholas Thatcher
Journal:  Lung Cancer       Date:  2005-09       Impact factor: 5.705

2.  The controversial role of surgery in stage III NSCLC.

Authors:  Jan P van Meerbeeck
Journal:  Lancet Oncol       Date:  2008-07       Impact factor: 41.316

3.  Patterns of surgical care of lung cancer patients.

Authors:  Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

4.  Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.

Authors:  Matthew Koshy; Stacey A Fedewa; Renu Malik; Mark K Ferguson; Wickii T Vigneswaran; Lawrence Feldman; Andrew Howard; Khaled Abdelhady; Ralph R Weichselbaum; Katherine S Virgo
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

5.  Predictors of mortality after surgical management of lung cancer in the National Cancer Database.

Authors:  Joshua E Rosen; Jacquelyn G Hancock; Anthony W Kim; Frank C Detterbeck; Daniel J Boffa
Journal:  Ann Thorac Surg       Date:  2014-10-18       Impact factor: 4.330

6.  Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.

Authors:  David W Johnstone; Roger W Byhardt; David Ettinger; Charles B Scott
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-10-01       Impact factor: 7.038

7.  Effect of tumor size on prognosis in patients treated with radical radiotherapy or chemoradiotherapy for non-small cell lung cancer. An analysis of the staging project database of the International Association for the Study of Lung Cancer.

Authors:  David Ball; Alan Mitchell; Dori Giroux; Ramon Rami-Porta
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

8.  The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer.

Authors:  Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2009-09       Impact factor: 15.609

9.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Gerard A Silvestri; Anne V Gonzalez; Michael A Jantz; Mitchell L Margolis; Michael K Gould; Lynn T Tanoue; Loren J Harris; Frank C Detterbeck
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.

Authors:  Hale B Caglar; Elizabeth H Baldini; Megan Othus; Michael S Rabin; Raphael Bueno; David J Sugarbaker; Steven J Mentzer; Pasi A Jänne; Bruce E Johnson; Aaron M Allen
Journal:  Cancer       Date:  2009-09-15       Impact factor: 6.860

View more
  7 in total

1.  ESTS staging guidelines for non-small cell lung cancer: a good guide to best ever accuracy and high survival rate.

Authors:  Akif Turna
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

2.  Editorial on "upfront surgery as first-line therapy in selected patients with stage IIIA non-small cell lung cancer".

Authors:  Hongsheng Lin; Kun Qiao
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Postoperative radiotherapy option based on mediastinal lymph node reclassification for patients with pN2 non-small-cell lung cancer.

Authors:  J Jin; Y Xu; X Hu; M Chen; M Fang; Q Hang; M Chen
Journal:  Curr Oncol       Date:  2020-06-01       Impact factor: 3.677

4.  Effect of preoperative radiotherapy on overall survival in N2 non-small-cell lung cancer: a propensity score-matched analysis of Surveillance, Epidemiology, and End Results database.

Authors:  Yunan Wang; Yunliang Cao; Mengjia Wu; Yanyi Lu; Bo He; Lei Zhou; Wei Hu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-06-15

5.  The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis.

Authors:  Tingting Liu; Yanshu Mu; Jun Dang; Guang Li
Journal:  J Cancer       Date:  2019-06-24       Impact factor: 4.207

6.  Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series.

Authors:  Shao Feng; Zhang Qiang; Cheng Wanwan; Zeng Zhaozhun; Xie Yuewu; Fang Shencun
Journal:  Front Oncol       Date:  2022-03-29       Impact factor: 6.244

7.  The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.

Authors:  Hongxia Duan; Long Liang; Shuanshuan Xie; Changhui Wang
Journal:  BMC Cancer       Date:  2020-08-26       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.